Certara, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jon Resnick
- Full Time Employees
- 1,487
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 100 Overlook Center Princeton NJ United States of America 08540
- IPO Date
- Dec 11, 2020
- CIK
- 0001827090
- Website
- certara.com
- Similar Companies
- Business
- Certara, Inc. (Nasdaq: CERT) provides biosimulation software, technology-enabled services, and solutions for model-informed drug development (MIDD) in the biopharmaceutical industry; its core offerings include mechanistic and empirical biosimulation platforms such as Simcyp PBPK Simulator; empirical PK/PD biosimulation platform; scientific informatics platforms like D360 and Chemaxon products including Design Hub and JChem Engines; clinical outcomes databases; regulatory submissions authoring and management software; market access communication platforms; data standardization and compliance software; and services encompassing drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, health economics and outcomes research (HEOR), and real-world evidence solutions. Founded in 2008 through the combination of Tripos International and Pharsight Corporation and headquartered at 4 Radnor Corporate Center, Suite 350, Radnor, Pennsylvania, the company operates globally with offices in the U.S., Canada, U.K., France, Germany, Switzerland, India, Japan, China, Australia, the Netherlands, and the Philippines, serving over 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across more than 70 countries. In recent developments, Certara completed the acquisition of Chemaxon in October 2024 to enhance its scientific informatics and predictive biosimulation capabilities from discovery through commercialization, integrating precision chemistry tools into its D360 applications and Simcyp simulator while leveraging Certara.AI for improved drug discovery insights; the company relocated its corporate headquarters to Radnor, Pennsylvania in 2024 to support workforce growth and strengthen its presence in the life sciences hub near Philadelphia; and it reported preliminary first-quarter 2025 financial results in April 2025 with revenue of $106.0 million, up from $96.7 million in the prior year, alongside 12% bookings growth and a $100 million share repurchase authorization.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Cerrado Gold Inc. (CERT:CA) Q1 2026 Earnings Call Transcript
Ahead of hurricane season, Duke Energy Foundation awards $500,000 to strengthen storm preparedness across North Carolina
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Certara, Inc. (CERT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Certara to Participate in Upcoming Investor Conferences
CERTARA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm
CERTARA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript
Certara Q1 Earnings Call Highlights